Arun Pol, MD
Psychiatry · Duluth, GANPI 1205015534
Payments from drug & device makers
Across 599 payments — averaging $159.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$85K
- AbbVie$2K
- Johnson & Johnson$1K
- Alkermes, Inc.$743
- Tris Pharma Inc$696
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$695
- plus $5K from 25 others
What the payments were for
- Speaking & faculty fees$75,55079%
- Travel & lodging$4,9615%
- Food & beverage$14,73715%
- Education$540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 205 | $84,758 |
| AbbVie(2 entities) | 64 | $1,570 |
| Johnson & Johnson | 35 | $1,426 |
| Alkermes, Inc. | 11 | $743 |
| Tris Pharma Inc | 28 | $696 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 22 | $695 |
| Takeda Pharmaceuticals U.S.A., Inc. | 40 | $669 |
| Otsuka America Pharmaceutical, Inc. | 26 | $645 |
| Ironshore Pharmaceuticals Inc. | 20 | $513 |
| Corium, LLC | 14 | $469 |
| Neos Therapeutics, LP | 30 | $454 |
| Axsome Therapeutics, Inc. | 8 | $407 |
| Sunovion Pharmaceuticals Inc. | 22 | $356 |
| Teva Pharmaceuticals USA, Inc. | 3 | $311 |
| Vanda Pharmaceuticals Inc. | 12 | $308 |
| Lundbeck LLC | 12 | $189 |
| Bausch Health US, LLC | 10 | $174 |
| Jazz Pharmaceuticals Inc. | 2 | $142 |
| Vertical Pharmaceuticals, LLC | 7 | $116 |
| Noven Pharmaceuticals, Inc. | 1 | $114 |
| Neurocrine Biosciences, Inc. | 6 | $111 |
| E.r. Squibb & Sons, L.L.C. | 1 | $105 |
| Noven Therapeutics, LLC | 4 | $75 |
| Shire North American Group Inc | 4 | $59 |
| Adlon Therapeutics L.p. | 3 | $48 |
| Avion Pharmaceuticals | 3 | $47 |
| OWP Pharmaceuticals, Inc. | 2 | $39 |
| Tempus AI, Inc | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$78,164
- ARISTADA$1,456
- LYBALVI$990
- VRAYLAR$698
- SPRAVATO$510
- INVEGA SUSTENNA$384
- ARISTADA INITIO$364
- CAPLYTA$342
- Dyanavel XR$236
- Quillivant$236
- Quillichew ER$236
- Azstarys$230
- Jornay PM 20mg capsules (Bottle of 100)$179
- AUSTEDO$125
- Auvelity$125
- SUNOSI$122
- Xelstrym$114
- Fanapt$112
- Austedo XR$111
- COBENFY$105
How this compares
$95,303 in reported general payments places this provider in the 95th percentile of 900 psychiatry providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 20 | $29,488 |
| AbilifyAripiprazole | 23 | $15,193 |
| VyvanseLisdexamfetamine Dimesylate | 24 | $9,199 |
| Bupropion XlBupropion Hcl | 43 | $1,578 |
| Tiagabine Hcl | 12 | $1,161 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 23 | $692 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 29 | $578 |
| Lurasidone Hcl | 25 | $501 |
| Escitalopram Oxalate | 55 | $475 |
| Trazodone Hcl | 41 | $417 |
| Duloxetine Hcl | 22 | $376 |
| Divalproex Sodium ErDivalproex Sodium | 25 | $315 |
| Paroxetine Hcl | 22 | $279 |
| Buspirone Hcl | 24 | $269 |
| Alprazolam | 77 | $256 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $645 | $29,48820 claims |
| E.r. Squibb & Sons, L.L.C.Abilify | $105 | $15,19323 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $669 | $9,19924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 900 psychiatry providers in Georgia.
Other psychiatry in Duluth
- Robert RiesenbergAtlanta$51.1M
- Saundra Maass-RobinsonAtlanta$11.1M
- David PurselleAtlanta$7.4M
- Maria JohnsonDecatur$5.4M
- Bethany DavisAtlanta$4.4M
- Michael BanovMarietta$4.2M
- Michael MobleySavannah$2.9M
- Richard PettyLoganville$2.9M
- Felipe SuplicyRome$2.3M
- Angelo SambunarisAlpharetta$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.